Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Miransertib (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Expanded access; Therapeutic Use
- Sponsors ArQule
- 31 Jul 2021 Status changed from recruiting to completed.
- 19 Oct 2018 According to an ArQule media release, preliminary data from two patients treated as part of this trial was presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting.
- 27 Oct 2017 New trial record